Meredith McKean, MD, executive committee chair, Melanoma and Skin Cancer Research Program, executive committee chair, BRIDGE Program, Sarah Cannon Research Institute, discusses the rationale for combining fianlimab with cemiplimab-rwlc (Libtayo) in the treatment of patients with advanced melanoma and highlights long-term follow-up data with the combination. Notably, these phase 1 trial (NCT03005782) data were shared at the 2024 ESMO Congress.
2024
The Aged Male TME Promotes Melanoma Invasion and Therapeutic Resistance
Major Finding: Age-associated changes in male fibroblasts induce a phenotypic switch to invasive and resistant melanoma.
TH17 Cells May Serve as Biomarker in Metastatic Melanoma
TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.
Skin Cancer Care: A Growing Divide in Australia
Skin cancer is a major cause of illness in Australia.